<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Community-Based Medicine</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C67373B7-D390-4D49-BD31-1280BA65D1F5"><gtr:id>C67373B7-D390-4D49-BD31-1280BA65D1F5</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Nutt</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/382F3EEB-8130-4EB4-9046-EC4190AD6E07"><gtr:id>382F3EEB-8130-4EB4-9046-EC4190AD6E07</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Cowen</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/12EBA189-8D91-4AF2-937C-6173E26691B6"><gtr:id>12EBA189-8D91-4AF2-937C-6173E26691B6</gtr:id><gtr:firstName>Ania</gtr:firstName><gtr:surname>Korszun</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3846243B-BB69-4AF7-B145-F4A2A3AD1C80"><gtr:id>3846243B-BB69-4AF7-B145-F4A2A3AD1C80</gtr:id><gtr:firstName>Stafford</gtr:firstName><gtr:otherNames>Louis</gtr:otherNames><gtr:surname>Lightman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/76FC6962-8CDC-4ACB-96BE-F9FB63D9B0DA"><gtr:id>76FC6962-8CDC-4ACB-96BE-F9FB63D9B0DA</gtr:id><gtr:firstName>Timothy James</gtr:firstName><gtr:surname>Peters</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/75796967-4735-4846-8FD3-7549F3D7E108"><gtr:id>75796967-4735-4846-8FD3-7549F3D7E108</gtr:id><gtr:firstName>Deborah</gtr:firstName><gtr:surname>Sharp</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B1FE4EBC-AF3A-4AE4-A2ED-4BD58E1E2544"><gtr:id>B1FE4EBC-AF3A-4AE4-A2ED-4BD58E1E2544</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Conlon</gtr:otherNames><gtr:surname>O'Donovan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D1A1B6B4-A623-4BB9-BBAD-597DB2E0B795"><gtr:id>D1A1B6B4-A623-4BB9-BBAD-597DB2E0B795</gtr:id><gtr:firstName>Glyn</gtr:firstName><gtr:surname>Lewis</gtr:surname><gtr:orcidId>0000-0001-5205-8245</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0200243"><gtr:id>F21EDEAC-8C9A-4C2D-8B3A-1FA256554B55</gtr:id><gtr:title>Genetic clinical and ENdocrine Predictors of treatment Outcome in Depression (GENPOD)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0200243</gtr:grantReference><gtr:abstractText>There are now a wide range of antidepressants used to treat depression in primary care, but the two main types influence the neurotransmitters serotonin (5HT) or noradrenaline. We plan to investigate whether there are genetic, clinical or hormonal predictors of response to these two main types of antidepressant. We plan to carry out a clinical trial that will randomise people with depression to either of the two antidepressants. The antidepressants are equally effective overall, but it seems that some patients get better on one type and some on the other. If we can find out what predicts response it will help to target treatment and also understand more about how these tablets work. It might also help to provide a classification of different types of depression.</gtr:abstractText><gtr:technicalSummary>We propose to carry out a randomised controlled trial in which subjects with depression will be randomly allocated to either reboxetine, a noradrenaline reuptake inhibitor (NaRI) or paroxetine, a serotonin reuptake inhibitor (SSRI). Outcome will be measured at 6 weeks and 12 weeks with the Beck Depression Inventory. Recruitment will occur in primary care. Measurements will be made at baseline in order to provide data on possible predictors of response to either reboxetine or paroxetine. The predictors we will examine are: genetic polymorphism at the 5HT transporter, clinical severity of depression, and a measure of hypothalamopituitary dysfunction.</gtr:technicalSummary><gtr:fund><gtr:end>2008-05-22</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-02-23</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>635201</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Psychiatry, Psychology &amp; Neuroscience</gtr:department><gtr:description>Psychiatric Genetics Consortium</gtr:description><gtr:id>388A0497-5D80-47C3-AFC8-66705CF4D010</gtr:id><gtr:impact>Publication as listed</gtr:impact><gtr:outcomeId>avdfeCzoa1A-1</gtr:outcomeId><gtr:partnerContribution>They coordinate large GWAS studies on psychiatric disorders</gtr:partnerContribution><gtr:piContribution>Via links with IOP have contributed to the PGC</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Psychiatry, Psychology &amp; Neuroscience</gtr:department><gtr:description>GENDEP</gtr:description><gtr:id>69D91DFD-DD5A-4FA5-931B-6ACCBFD4FF53</gtr:id><gtr:impact>Publications that are included</gtr:impact><gtr:outcomeId>Cf3aT9MydKi-1</gtr:outcomeId><gtr:partnerContribution>They have contributed data and also led the analysis on one paper.</gtr:partnerContribution><gtr:piContribution>This study and mine used very similar methods allowing joint use of the data for genetic analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Sheffield clinical presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A7459AAF-ABDA-42BC-AC69-B6BCBEB8C3D9</gtr:id><gtr:impact>30 people attended.

None</gtr:impact><gtr:outcomeId>hhrWrdXXFM2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lectures and presentations</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>30E436E1-01CC-4D7C-8FB9-13962B372A77</gtr:id><gtr:impact>Lectures to psychiatrists and other health professionals

None at present</gtr:impact><gtr:outcomeId>BB0B79351A9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Psychiatric trainees in Southmead hospital</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2276D778-64F5-4CA8-96B7-BD4054E341F5</gtr:id><gtr:impact>40 people attended the talk - part of the postgraduate education of clinicians.

None noted.</gtr:impact><gtr:outcomeId>MysBmQvPksa</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1260000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR HTA</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>06/404/02</gtr:fundingRef><gtr:id>56F1F7BA-5346-43A4-8B73-45CEA131F351</gtr:id><gtr:outcomeId>hYRepiCSnio</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Programmes for Applied Research</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>7AE9CEB6-898B-4985-827D-988C528B83DA</gtr:id><gtr:outcomeId>qxKzJwJstpE0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>900000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Health Technology Assessment Programme (HTA)</gtr:department><gtr:description>Health Technology Assessment</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>03/45/07</gtr:fundingRef><gtr:id>0D042538-8103-4C1C-AE92-CEA72D1B0814</gtr:id><gtr:outcomeId>F0212D660730</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>This study was a stratified medicine design to refine the indications for existing antidepressants</gtr:description><gtr:id>11616090-D7CF-499E-986A-EBEC48A27280</gtr:id><gtr:impact>We could not identify factors that refined the indication for the antidepressants</gtr:impact><gtr:outcomeId>PfpgmBHPNr7</gtr:outcomeId><gtr:stage>Wide-scale adoption</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>GENPOD</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://en.wikipedia.org/wiki/Citalopram</gtr:url></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1BB60BE1-0633-49D2-844B-27EB126A61E2</gtr:id><gtr:title>GENetic and clinical predictors of treatment response in depression: the GenPod randomised trial protocol.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0a285263b645daba67172396207305c"><gtr:id>c0a285263b645daba67172396207305c</gtr:id><gtr:otherNames>Thomas L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>43261E2AC7A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>608F4B7A-5B14-4377-9CD0-D2FCB7B69B35</gtr:id><gtr:title>Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/713660ead41c80ab7e4d0ae0edb2d7a8"><gtr:id>713660ead41c80ab7e4d0ae0edb2d7a8</gtr:id><gtr:otherNames>Bould H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>pm_12974_24_22223618</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90005D8E-D746-4F34-BE9C-69FEA7FE6DEE</gtr:id><gtr:title>Genetic predictors of antidepressant side effects: a grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9bdc076a47d54fe530e58d4a3dfeaf81"><gtr:id>9bdc076a47d54fe530e58d4a3dfeaf81</gtr:id><gtr:otherNames>Hodgson K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>doi_55f9839836ba1da5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5673A468-B61E-43D2-8AE7-C9DD185103E6</gtr:id><gtr:title>A mega-analysis of genome-wide association studies for major depressive disorder.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5db0eb8b13df5e1e75fa2ab2fd52a218"><gtr:id>5db0eb8b13df5e1e75fa2ab2fd52a218</gtr:id><gtr:otherNames>Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>pm_12974_24_22472876</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30DD35FD-9696-4EF2-95E6-C6099A7B4D43</gtr:id><gtr:title>Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56ada3ea3786a6a31983bfd2ca653851"><gtr:id>56ada3ea3786a6a31983bfd2ca653851</gtr:id><gtr:otherNames>Tansey KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>pm_12974_24_23091423</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F06265A-E762-4CF7-AD3A-6EDD00B712D7</gtr:id><gtr:title>Are multiple physical symptoms a poor prognostic factor or just a marker of depression severity? Secondary analysis of the GenPod trial.</gtr:title><gtr:parentPublicationTitle>Journal of affective disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4e5e248878a874673b0e17efd75d4d0"><gtr:id>e4e5e248878a874673b0e17efd75d4d0</gtr:id><gtr:otherNames>Green A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0165-0327</gtr:issn><gtr:outcomeId>545b652ad10626.54895279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3803041F-8FC9-44E8-9EE4-D6B72AA79861</gtr:id><gtr:title>Severity of depression and response to antidepressants: GENPOD randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cc5bc13f58983c9a0e889e75f778d2f"><gtr:id>5cc5bc13f58983c9a0e889e75f778d2f</gtr:id><gtr:otherNames>Wiles NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>pm_12974_24_22194183</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A0277FE-AB2C-46E6-82D8-1AEDE78F4A15</gtr:id><gtr:title>Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed08299b1df15630499f2ebf2f829344"><gtr:id>ed08299b1df15630499f2ebf2f829344</gtr:id><gtr:otherNames>Lewis G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>58af272c0af6b3.11118392</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C4D1F9B-F2C3-4D96-8AE7-2D0CD7E0898E</gtr:id><gtr:title>An Analysis of Two Genome-wide Association Meta-analyses Identifies a New Locus for Broad Depression Phenotype.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ace8946fba7585db3d6c6f494a45032"><gtr:id>0ace8946fba7585db3d6c6f494a45032</gtr:id><gtr:otherNames>Direk N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>5a34fd7a176427.08032003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72C4447F-42BC-42D9-B663-ADCC6E16EA30</gtr:id><gtr:title>Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be3fa3fb654e64f7faacf89e72f3d5fc"><gtr:id>be3fa3fb654e64f7faacf89e72f3d5fc</gtr:id><gtr:otherNames>Crawford AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>545b686b4ac1c4.59954056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB9BB4A9-67BD-48D9-ACBB-AA2B5AF68438</gtr:id><gtr:title>GPs' experiences of primary care mental health research: a qualitative study of the barriers to recruitment.</gtr:title><gtr:parentPublicationTitle>Family practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e491475a74d8f032ad15dbd5b74dd5f3"><gtr:id>e491475a74d8f032ad15dbd5b74dd5f3</gtr:id><gtr:otherNames>Mason V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0263-2136</gtr:issn><gtr:outcomeId>AD2CF7A9313</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E81A1CD1-FA13-46BE-A6C2-34AD187D4569</gtr:id><gtr:title>Involving patients with depression in research: survey of patients' attitudes to participation.</gtr:title><gtr:parentPublicationTitle>The British journal of general practice : the journal of the Royal College of General Practitioners</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d018994a5204fea59d627a395b09d25"><gtr:id>2d018994a5204fea59d627a395b09d25</gtr:id><gtr:otherNames>Tallon D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0960-1643</gtr:issn><gtr:outcomeId>SeyeQputQmN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6E54C67-63DC-494B-96C5-8754FA7F885A</gtr:id><gtr:title>Contribution of common genetic variants to antidepressant response.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56ada3ea3786a6a31983bfd2ca653851"><gtr:id>56ada3ea3786a6a31983bfd2ca653851</gtr:id><gtr:otherNames>Tansey KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>pm_12974_24_23237317</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B35636EE-48DC-4B1E-BF3E-AD7B0EC2FF44</gtr:id><gtr:title>Copy number variants and therapeutic response to antidepressant medication in major depressive disorder.</gtr:title><gtr:parentPublicationTitle>The pharmacogenomics journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56ada3ea3786a6a31983bfd2ca653851"><gtr:id>56ada3ea3786a6a31983bfd2ca653851</gtr:id><gtr:otherNames>Tansey KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-269X</gtr:issn><gtr:outcomeId>58af272a92a4c1.11271111</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5B8244F-29F4-4AFF-BF1E-6A7AB34443FD</gtr:id><gtr:title>Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram versus reboxetine): an example from the GENPOD trial.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cc5bc13f58983c9a0e889e75f778d2f"><gtr:id>5cc5bc13f58983c9a0e889e75f778d2f</gtr:id><gtr:otherNames>Wiles NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>doi_55f9839836b13a8e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3531434B-BCBF-4567-AD82-90B98FC6247B</gtr:id><gtr:title>Genetic susceptibility for bipolar disorder and response to antidepressants in major depressive disorder.</gtr:title><gtr:parentPublicationTitle>American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56ada3ea3786a6a31983bfd2ca653851"><gtr:id>56ada3ea3786a6a31983bfd2ca653851</gtr:id><gtr:otherNames>Tansey KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1552-4841</gtr:issn><gtr:outcomeId>58af272ab46997.23253271</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0200243</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>